QTTB
Q32 Bio Inc.Company Information
- Company Name
- Q32 Bio Inc.
- CIK
- CIK0001661998
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- QTTB: Nasdaq, FIXX: CBOE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- QTTB
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-05-28
- Last sale
- 2026-08-25
- Shares purchased (TTM)
- 3,750,000
- Shares sold (TTM)
- 82,623
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 21,927,023
- Shares outstanding
- 20,342,345
- Ownership
- 107.79%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -8.85%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 106 | 51 | 48 | 49 | 55 | 65 | 78 | 89 | 98 | 116 | 26 | 36 | ||||||
| Short Term Investments | - | - | - | - | - | - | - | - | - | - | - | 74 | ||||||
| Available For Sale Securities Debt Securities Current | - | - | - | - | - | - | - | - | 10 | 20 | 43 | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 6 | 7 | 2 | 3 | 3 | 4 | 5 | 4 | 3 | 3 | 3 | ||||||
| Assets Current | 110 | 57 | 55 | 51 | 58 | 69 | 82 | 94 | 112 | 138 | 29 | 107 | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | - | - | - | - | 14 | ||||||
| Assets Held For Sale Not Part Of Disposal Group | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Equity Method Investment Aggregate Cost | - | - | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 5 | 0 | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 0 | ||||||
| Operating Lease Right Of Use Asset | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 19 | ||||||
| Restricted Cash And Cash Equivalents Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | - | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 5 | - | ||||||
| Assets | 116 | 64 | 62 | 58 | 66 | 79 | 92 | 105 | 124 | 152 | 47 | 140 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 2 | 5 | 3 | 8 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | 1 | 2 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Lines Of Credit Current | 0 | 6 | 6 | 6 | 6 | 5 | 3 | 2 | 0 | 3 | 1 | - | ||||||
| Liabilities Current | 5 | 11 | 11 | 11 | 12 | 15 | 16 | 14 | 17 | 33 | 14 | 25 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 6 | 27 | ||||||
| Long Term Line Of Credit | 0 | 2 | 3 | 5 | 7 | 8 | 10 | 11 | 13 | 9 | 5 | - | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 55 | - | ||||||
| Convertible Debt Noncurrent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 39 | - | ||||||
| Liabilities | 10 | 17 | 20 | 76 | 78 | 83 | 87 | 86 | 91 | 104 | 119 | 52 | ||||||
Stockholders Equity | ||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 111 | - | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 327 | 259 | 247 | 244 | 243 | 242 | 240 | 239 | 237 | 235 | 4 | 614 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | 0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -222 | -213 | -205 | -263 | -255 | -246 | -235 | -221 | -203 | -186 | -187 | -526 | ||||||
| Stockholders Equity | 106 | 46 | 42 | -18 | -12 | -4 | 6 | 18 | 34 | 49 | -183 | -156 | ||||||
| Liabilities And Stockholders Equity | 116 | 64 | 62 | 58 | 66 | 79 | 92 | 105 | 124 | 152 | 47 | 140 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 200 | ||||||
| Common Stock Shares Issued | 24 | 15 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 0 | 58 | ||||||
| Shares Outstanding | 24 | 15 | 13 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 0 | 58 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialQ32 Bio Inc. (QTTB) — SEC Financial Statements & Analysis
Q32 Bio Inc. (QTTB) is a pharmaceutical preparations company, incorporated in DE. Q32 Bio Inc. trades on Nasdaq, CBOE as: QTTB, FIXX. Q32 Bio Inc. (QTTB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Q32 Bio Inc. carries a market cap of $259.16M, a P/E ratio of 7.67x, a P/B ratio of 2.45x, a P/S ratio of -54.14x, an enterprise value of $152.24M, and an EV/EBITDA multiple of 6.98x. On profitability, it posts an operating margin of 777.58%, a net margin of 609.03%, a Return on Equity (ROE) of 72.14%, and a Return on Assets (ROA) of 37.13%. Per share, it reports EPS of $1.66, diluted EPS of $1.66, free cash flow per share of $-0.97, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -164.60% year-over-year, and EPS growth of -138.73% year-over-year. On the balance sheet, it maintains a current ratio of 20.30x, a quick ratio of 19.68x, working capital of $104.25M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.09, free cash flow of $-19.83M (TTM), and net debt of $-106.92M. Figures sourced from SEC EDGAR.
- Market Cap
- $259.16M
- P/E TTM
- 7.67x
- EPS TTM
- $1.66
- P/B TTM
- 2.45x
- ROE TTM
- 72.14%
- ROA TTM
- 37.13%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-19.83M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Q32 Bio Inc. in?
Q32 Bio Inc. (QTTB) operates in the Pharmaceutical Preparations industry.
What exchange does QTTB trade on?
Q32 Bio Inc. (QTTB) trades on the Nasdaq, CBOE.
Where is Q32 Bio Inc. incorporated?
Q32 Bio Inc. is incorporated in DE.
When was Q32 Bio Inc. (QTTB)'s most recent SEC filing?
Q32 Bio Inc. (QTTB)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is QTTB's market cap?
Q32 Bio Inc. (QTTB) has a market capitalization of $259.16M as of 2026-06-30.
What is QTTB's P/E ratio?
Q32 Bio Inc. (QTTB)'s trailing twelve month P/E ratio is 7.67x as of 2026-06-30.
What is QTTB's EPS (earnings per share)?
Q32 Bio Inc. (QTTB)'s trailing twelve month EPS is $1.66 as of 2026-06-30.
What is QTTB's ROE (return on equity)?
Q32 Bio Inc. (QTTB)'s trailing twelve month Return on Equity (ROE) is 72.14% as of 2026-06-30.
What is QTTB's ROA (return on assets)?
Q32 Bio Inc. (QTTB)'s trailing twelve month Return on Assets (ROA) is 37.13% as of 2026-06-30.
What is QTTB's EV/EBITDA?
Q32 Bio Inc. (QTTB)'s trailing twelve month EV/EBITDA is 6.98x as of 2026-06-30.